Marker Therapeutics (MRKR) Asset Utilization Ratio (2016 - 2025)
Marker Therapeutics (MRKR) posted quarterly Asset Utilization Ratio of 0.17 for Q4 2025, down 61.43% year-over-year from 0.45 in Q4 2024, and down 32.42% quarter-over-quarter from 0.26 in Q3 2025.
Marker Therapeutics (MRKR) Asset Utilization Ratio (2016 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has reported Asset Utilization Ratio for 9 consecutive years, with 0.17 the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Utilization Ratio fell 61.43% year-over-year to 0.17; the TTM figure through Dec 2025 stood at 0.17 (down 61.43% YoY), while the FY2025 annual figure was 0.17, down 48.73% from the prior year.
- Asset Utilization Ratio declined to 0.17 in Q4 2025 per MRKR's latest filing, from 0.26 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.46 in Q3 2024 and bottomed at 0.02 in Q1 2022.
- Historically, Asset Utilization Ratio has averaged 0.2 across 4 years, with a median of 0.16 in 2023.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio surged 580.59% — and 2025, when it tumbled 61.43%.
- Marker Therapeutics' Asset Utilization Ratio stood at 0.09 in 2022, then jumped by 32.38% to 0.12 in 2023, then surged by 265.98% to 0.45 in 2024, then sank by 61.43% to 0.17 in 2025.
- Business Quant data shows MRKR's Asset Utilization Ratio at 0.17 in Q4 2025, 0.26 in Q3 2025, and 0.34 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 0.13 |
| 10 | Marker Therapeutics | 26.27 Mn | 14.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.17 |
| Sep 30, 2025 | 0.26 |
| Jun 30, 2025 | 0.34 |
| Mar 31, 2025 | 0.33 |
| Dec 31, 2024 | 0.45 |
| Sep 30, 2024 | 0.46 |
| Jun 30, 2024 | 0.27 |
| Mar 31, 2024 | 0.06 |
| Dec 31, 2023 | 0.12 |
| Sep 30, 2023 | 0.15 |
| Jun 30, 2023 | 0.15 |
| Mar 31, 2023 | 0.16 |
| Dec 31, 2022 | 0.09 |
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | 0.03 |
| Mar 31, 2022 | 0.02 |
| Dec 31, 2020 | 0.01 |
| Sep 30, 2020 | 0.01 |
| Jun 30, 2020 | 0.01 |
| Dec 31, 2019 | 0.00 |